Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized double-blind, placebo-controlled, parallel-group, fixed single-dose regimen (SR141716 [rimonabant] 20 mg), multicenter study to assess the efficacy and safety of SR141716 in obese patients with dyslipidemia.

Next Previous
X
Search
Trial Profile

A randomized double-blind, placebo-controlled, parallel-group, fixed single-dose regimen (SR141716 [rimonabant] 20 mg), multicenter study to assess the efficacy and safety of SR141716 in obese patients with dyslipidemia.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2009

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Dyslipidaemias; Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms VENUS
  • Sponsors Sanofi

    • Most Recent Events

    • 21 Jul 2009 Actual patient number (915) added as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
    • 05 Nov 2008 Status changed from active, no longer recruiting to discontinued., as reported by sanofi-aventis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top